{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:39:54Z","timestamp":1792096794107,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre (NCN, Poland)","doi-asserted-by":"publisher","award":["UMO 2015\/19\/B\/ST5\/00231"],"award-info":[{"award-number":["UMO 2015\/19\/B\/ST5\/00231"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001654","name":"DAAD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001654","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Stays for University Academics and Scientists","award":["57314018"],"award-info":[{"award-number":["57314018"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ejmech.2019.02.009","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T12:39:20Z","timestamp":1549283960000},"page":"96-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Synthesis, docking and antibacterial studies of more potent amine and hydrazone rifamycin congeners than rifampicin"],"prefix":"10.1016","volume":"167","author":[{"given":"Krystian","family":"Pyta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Janas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Szukowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Pecyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelina","family":"Jaworska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzena","family":"Gajecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Bartl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8072-5877","authenticated-orcid":false,"given":"Piotr","family":"Przybylski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.02.009_bib1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1021\/cr030112j","article-title":"Rifamycin mode of action, resistance, and biosynthesis","volume":"105","author":"Floss","year":"2005","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2019.02.009_bib2","series-title":"Chronicles of Drug Discovery","first-page":"201","article-title":"Rifampicin","author":"Sensi","year":"1982"},{"key":"10.1016\/j.ejmech.2019.02.009_bib3","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ijantimicag.2011.01.018","article-title":"Increased rifampicin resistance in blood isolates of meticillin-resistant Staphylococcus aureus (MRSA) amongst patients exposed to rifampicin-containing antituberculous treatment","volume":"37","author":"Tan","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2019.02.009_bib4","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/clpt.2011.129","article-title":"Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis","volume":"90","author":"Ngaimisi","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2019.02.009_bib5","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.bmcl.2006.12.026","article-title":"Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins","volume":"17","author":"Kim","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.02.009_bib6","doi-asserted-by":"crossref","first-page":"114758","DOI":"10.1039\/C6RA22880A","article-title":"Semi-synthetic zwitterionic rifamycins: a promising class of antibiotics; Survey of their chemistry and biological activities","volume":"6","author":"Bujnowski","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2019.02.009_bib7","doi-asserted-by":"crossref","first-page":"8283","DOI":"10.1039\/c2ob26317c","article-title":"A\u00a0new model of binding of rifampicin and its amino analogues as zwitterions to bacterial RNA polymerase","volume":"10","author":"Pyta","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","article-title":"Structural mechanism for rifampicin inhibition of bacterial RNA polymerase","volume":"104","author":"Campbell","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2019.02.009_bib9","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/sj.emboj.7600499","article-title":"Structural, functional, and genetic analysis of sorangicin inhibition of bacterial RNA polymerase","volume":"24","author":"Campbell","year":"2005","journal-title":"EMBO (Eur. Mol. Biol. Organ.) J."},{"key":"10.1016\/j.ejmech.2019.02.009_bib10","doi-asserted-by":"crossref","first-page":"14820","DOI":"10.1073\/pnas.0802822105","article-title":"Rifamycins do not function by allosteric modulation of binding of Mg2+ to the RNA polymerase active center","volume":"105","author":"Feklistov","year":"2008","journal-title":"Proceed. Nat. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2019.02.009_bib11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.cell.2005.07.014","article-title":"Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins","volume":"122","author":"Artsimovitch","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2019.02.009_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0223-5234(89)90103-7","article-title":"Mechanism of inhibition of DNA-dependent RNA polymerase of Escherichia coli by rifamycins","volume":"24","author":"Cella","year":"1989","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib13","doi-asserted-by":"crossref","first-page":"9126","DOI":"10.1074\/jbc.M112.430900","article-title":"X-ray crystal structure of Escherichia coli RNA polymerase \u03c370 holoenzyme","volume":"288","author":"Murakami","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2174\/092986709787315559","article-title":"Bacterial RNA polymerase inhibitors: an organized overview of their structure, derivatives, biological activity and current clinical development status","volume":"16","author":"Mariani","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib15","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-016-1785-7","article-title":"In\u00a0vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa","volume":"16","author":"Hu","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ejmech.2019.02.009_bib16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejmech.2011.10.041","article-title":"Pharmacophore insights into rpoB gene mutations in Mycobacterium tuberculosis rifampicin resistant isolates","volume":"47","author":"Figueiredo","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib17","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1039\/c2ob00008c","article-title":"Intramolecular proton transfer impact on antibacterial properties of ansamycin antibiotic rifampicin and its new amino analogues","volume":"10","author":"Pyta","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib18","doi-asserted-by":"crossref","first-page":"5604","DOI":"10.1128\/AAC.01137-16","article-title":"Rifamycin resistance in Clostridium difficile is generally associated with a low fitness burden","volume":"60","author":"Dang","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.02.009_bib19","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.5588\/ijtld.14.0936","article-title":"Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations","volume":"19","author":"El Maraachli","year":"2015","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.ejmech.2019.02.009_bib20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/ja.2014.107","article-title":"Resistance to rifampicin: a review","volume":"67","author":"Goldstein","year":"2014","journal-title":"J.\u00a0Antibiot."},{"key":"10.1016\/j.ejmech.2019.02.009_bib21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1089\/mdr.2011.0010","article-title":"Fitness and molecular mechanisms of resistance to rifaximin in in\u00a0vitro selected Escherichia coli mutants","volume":"18","author":"Pons","year":"2012","journal-title":"Microb. Drug Resist."},{"key":"10.1016\/j.ejmech.2019.02.009_bib22","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/mmi.13606","article-title":"Structural basis for rifamycin resistance of bacterial RNA polymerase by the three most clinically important RpoB mutations found in","volume":"103","author":"Molodtsov","year":"2017","journal-title":"Mycobacterium tuberculosis. Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2019.02.009_bib23","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1128\/AAC.04374-14","article-title":"Molecular analysis of codon 548 in the rpoB gene involved in Mycobacterium tuberculosis resistance to rifampin","volume":"59","author":"Horng","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.02.009_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-5-137","article-title":"Few amino acid positions in rpoB are associated with most of the rifampin resistance in Mycobacterium tuberculosis","volume":"5","author":"Cummings","year":"2004","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.ejmech.2019.02.009_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/srep43858","article-title":"A\u00a0temporal proteome dynamics study reveals the molecular basis of induced phenotypic resistance in Mycobacterium smegmatis at sub-lethal rifampicin concentrations","volume":"7","author":"Giddey","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2019.02.009_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11343","article-title":"Rifampin phosphotransferase is an unusual antibiotic resistance kinase","volume":"7","author":"Stogios","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2019.02.009_bib27","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1128\/AAC.37.6.1313","article-title":"Inactivation of rifampin by Nocardia brasiliensis","volume":"37","author":"Yazawa","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.02.009_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ja.2009.116","article-title":"Monooxygenation of rifampicin catalyzed by the rox gene product of Nocardia farcinica: structure elucidation, gene identification and role in drug resistance","volume":"63","author":"Hoshino","year":"2010","journal-title":"J.\u00a0Antibiot."},{"key":"10.1016\/j.ejmech.2019.02.009_bib29","doi-asserted-by":"crossref","first-page":"14248","DOI":"10.1074\/jbc.M116.716704","article-title":"Rifampin resistance mutations are associated with broad chemical remodeling of mycobacterium tuberculosis","volume":"291","author":"Lahiri","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib30","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1016\/j.tet.2012.04.071","article-title":"Rifamycin antibiotics - new compounds and synthetic methods. Part 3: study of the reaction of 3-formylrifamycin SV with primary amines and ketones","volume":"68","author":"Bujnowski","year":"2012","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2019.02.009_bib31","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tet.2014.10.079","article-title":"Rifamycin antibiotics - new compounds and synthetic methods. Part 4: study of the reaction of 3-formylrifamycin SV with secondary amines and ketones","volume":"71","author":"Bujnowski","year":"2015","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2019.02.009_bib32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.toxlet.2013.05.005","article-title":"Mechanisms of P-gp inhibition and effects on membrane fluidity of a new rifampicin derivative, 1,8-dibenzoyl-rifampicin","volume":"220","author":"Vilas-Boas","year":"2013","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.ejmech.2019.02.009_bib33","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1021\/jm201716n","article-title":"Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases","volume":"55","author":"Gill","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib34","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1021\/jm4004889","article-title":"X-ray crystal structures of the Escherichia coli RNA polymerase in complex with benzoxazinorifamycins","volume":"56","author":"Molodtsov","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib35","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1039\/C7OB00614D","article-title":"Potential antibiotics from locust-associated actinobacteria Amycolatopsis sp","volume":"15","author":"Xiao","year":"2017","journal-title":"Hca4. Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejmech.2014.08.066","article-title":"SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development","volume":"86","author":"Poce","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib37","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ejmech.2014.07.066","article-title":"Structure and evaluation of antibacterial and antitubercular properties of new basic and heterocyclic 3-formylrifamycin SV derivatives obtained via \u2018click chemistry\u2019 approach","volume":"84","author":"Pyta","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib38","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.molstruc.2017.10.083","article-title":"Crystalline structure of the marketed form of Rifampicin: a case of conformational and charge transfer polymorphism","volume":"1155","author":"de Pinho Pessoa Nogueira","year":"2018","journal-title":"J.\u00a0Mol. Struct."},{"key":"10.1016\/j.ejmech.2019.02.009_bib39","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1021\/jm00330a013","article-title":"A\u00a0new class of active semisynthetic rifamycins. N-substituted aminomethyl derivatives of rifamycin SV","volume":"8","author":"Maggi","year":"1965","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib40","first-page":"704","article-title":"Hydrazones of 3 formylrifamycin SV. Part III. N(mono and di)substituted hydrazone derivatives: synthesis, antibacterial activity and other biological properties","volume":"30","author":"Cricchio","year":"1975","journal-title":"Farmaco, Ed. Sci."},{"key":"10.1016\/j.ejmech.2019.02.009_bib41","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1021\/jm00308a042","article-title":"The influence of the carboxyl group upon the antibacterial activity of rifamycins","volume":"11","author":"Maggi","year":"1968","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib42","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1021\/jm00220a009","article-title":"3-N-substituted derivatives of rifamycin SV. A convenient method of synthesis, cyclization of certain derivatives, and anticellular and antiviral activities of several derivatives","volume":"20","author":"McCarthy","year":"1977","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib43","doi-asserted-by":"crossref","DOI":"10.1021\/jm00255a008","article-title":"Rifamycin derivatives as inhibitors of a ribonucleic acid instructed deoxyribonucleic acid polymerase function. Effect of lipophilicity","volume":"17","author":"Tischler","year":"1974","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib44","first-page":"1367","article-title":"Rifamycins as inhibitors of retroviral reverse transcriptase from M-MuLV, RAV-2, and HIV-1","volume":"47","author":"Bartolucci","year":"1992","journal-title":"Farmaco"},{"key":"10.1016\/j.ejmech.2019.02.009_bib45","doi-asserted-by":"crossref","DOI":"10.1021\/jm00164a013","article-title":"Hypolipidemic activity of rifamycin derivatives","volume":"33","author":"Traxler","year":"1990","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.009_bib46","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/cphc.201402892","article-title":"Regioselective long-range proton transfer in new rifamycin antibiotics: a process in which crown ethers act as stronger br\u00f8nsted bases than amines","volume":"16","author":"Pyta","year":"2015","journal-title":"ChemPhysChem"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419301199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419301199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:49:10Z","timestamp":1759326550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419301199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":46,"alternative-id":["S0223523419301199"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.02.009","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis, docking and antibacterial studies of more potent amine and hydrazone rifamycin congeners than rifampicin","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}